Condition
Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05377827Phase 1Active Not Recruiting
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
NCT05475925Phase 1Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Showing all 2 trials